These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 26003861)

  • 21. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease.
    Mandal PK; Akolkar H; Tripathi M
    J Alzheimers Dis; 2012; 31 Suppl 3():S75-86. PubMed ID: 22426021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer's disease.
    Hänggi J; Streffer J; Jäncke L; Hock C
    J Alzheimers Dis; 2011; 26(4):719-34. PubMed ID: 21709375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials.
    Verma N; Beretvas SN; Pascual B; Masdeu JC; Markey MK;
    Curr Alzheimer Res; 2018 Mar; 15(5):429-442. PubMed ID: 29110613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
    Wang T; Xiao S; Li X; Ding B; Ling H; Chen K; Fang Y
    Int Psychogeriatr; 2012 Jan; 24(1):19-27. PubMed ID: 21676281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH; Kim M; Moon SY; Yong SW; Hong JM
    J Neurol Sci; 2015 Aug; 355(1-2):174-9. PubMed ID: 26076880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive MMN and P300 in mild cognitive impairment and Alzheimer's disease: A high density EEG-3D vector field tomography approach.
    Papadaniil CD; Kosmidou VE; Tsolaki A; Tsolaki M; Kompatsiaris IY; Hadjileontiadis LJ
    Brain Res; 2016 Oct; 1648(Pt A):425-433. PubMed ID: 27485659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment.
    Habert MO; Horn JF; Sarazin M; Lotterie JA; Puel M; Onen F; Zanca M; Portet F; Touchon J; Verny M; Mahieux F; Giron A; Fertil B; Dubois B
    Neurobiol Aging; 2011 Jan; 32(1):15-23. PubMed ID: 19250707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
    Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects.
    Wood PL; Barnette BL; Kaye JA; Quinn JF; Woltjer RL
    Acta Neuropsychiatr; 2015 Oct; 27(5):270-8. PubMed ID: 25858158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.
    Olsson B; Hertze J; Lautner R; Zetterberg H; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Blennow K; Hansson O
    J Alzheimers Dis; 2013; 33(1):45-53. PubMed ID: 22890100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How early can we predict Alzheimer's disease using computational anatomy?
    Adaszewski S; Dukart J; Kherif F; Frackowiak R; Draganski B;
    Neurobiol Aging; 2013 Dec; 34(12):2815-26. PubMed ID: 23890839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Hallikainen M; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Meta-Analysis of fMRI Activation Differences during Episodic Memory in Alzheimer's Disease and Mild Cognitive Impairment.
    Terry DP; Sabatinelli D; Puente AN; Lazar NA; Miller LS
    J Neuroimaging; 2015; 25(6):849-60. PubMed ID: 26076800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural Dynamics of Multiple Object Processing in Mild Cognitive Impairment and Alzheimer's Disease: Future Early Diagnostic Biomarkers?
    Bagattini C; Mazza V; Panizza L; Ferrari C; Bonomini C; Brignani D
    J Alzheimers Dis; 2017; 59(2):643-654. PubMed ID: 28671112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.
    Brueggen K; Dyrba M; Barkhof F; Hausner L; Filippi M; Nestor PJ; Hauenstein K; Klöppel S; Grothe MJ; Kasper E; Teipel SJ
    J Alzheimers Dis; 2015; 48(1):197-204. PubMed ID: 26401940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition.
    Tokuchi R; Hishikawa N; Kurata T; Sato K; Kono S; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2014 Nov; 346(1-2):288-92. PubMed ID: 25248955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.